Interventions for managing medication-related osteonecrosis of the jaw
Tóm tắt
Từ khóa
Tài liệu tham khảo
Freiberger, 2012, What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics, Journal of Oral and Maxillofacial Surgery, 70, 1573, 10.1016/j.joms.2012.04.001
NCT00462098 Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates clinicaltrials.gov/show/NCT00462098
Mozzati, 2012, Tooth extraction in patients on zoledronic acid therapy, Oral Oncology, 48, 817, 10.1016/j.oraloncology.2012.03.009
Mozzati, 2011, A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study, Joint, Bone, Spine, 786, 648, 10.1016/j.jbspin.2011.04.017
Mozzati, 2013, Tooth extraction in osteoporotic patients taking oral bisphosphonates, Osteoporosis International, 24, 1707, 10.1007/s00198-012-2239-8
Mozzati, 2011, Tooth extraction and oral bisphosphonates: comparison of different surgical protocol, Joint, Bone, Spine, 78, 647, 10.1016/j.jbspin.2011.04.018
Mücke, 2016, Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years, Journal of Cranio-maxillo-facial Surgery, 44, 1689, 10.1016/j.jcms.2016.07.026
Ristow, 2017, Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study, International Journal of Oral and Maxillofacial Surgery, 46, 157, 10.1016/j.ijom.2016.10.008
Asaka T Ohga N Yamazaki Y Sato J Satoh C Kitagawa Y Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study Clinical Oral Investigations 10.1007/s00784-016-2004-z
Bonacina, 2011, Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients, Journal (Canadian Dental Association), 77, b147
Bramati, 2015, Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases, Journal of Bone and Mineral Metabolism, 33, 119, 10.1007/s00774-014-0566-x
Coviello, 2012, Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients, Journal of Biological Regulators and Homeostatic Agents, 26, 151
Iuliis, 2014, Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates, Anticancer Research, 34, 2477
Dimopoulos, 2009, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid, Annals of Oncology, 20, 117, 10.1093/annonc/mdn554
Lee, 2014, Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws, Journal of the Formosan Medical Association, 113, 166-72, 10.1016/j.jfma.2012.04.010
Montebugnoli, 2007, Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 104, 473, 10.1016/j.tripleo.2007.01.008
Pelaz, 2014, Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: apilot study comparing fibrin rich in growth factors and teriparatide, Medicina Oral, Patologia Oral y Cirugia Bucal, 19, e320-6
Vescovi, 2010, Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT), Lasers in Medical Science, 25, 101-13, 10.1007/s10103-009-0687-y
Vescovi, 2012, Surgical approach and laser applications in BRONJ osteoporotic and cancer patients, Journal of Osteoporosis, 2012, Article ID 5854, 10.1155/2012/585434
ACTRN12612000950864 Does teriparatide reverse osteonecrosis of the jaw in patients treated with either bisphosphonates or denosumab? A randomised, controlled trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362988
NCT01526915 Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates (OCN/PRF) clinicaltrials.gov/ct2/show/record/NCT01526915
NCT02198001 Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction (PRF) clinicaltrials.gov/ct2/show/record/NCT02198001
UMIN000009132 Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000010706&language=E
Anzures-Cabrera, 2010, Graphical displays for meta-analysis: an overview with suggestions for practice, Research Synthesis Methods, 1, 66, 10.1002/jrsm.6
Badros, 2008, Natural history of osteonecrosis of the jaw in patients with multiple myeloma, Journal of Clinical Oncology, 26, 5904, 10.1200/JCO.2008.16.9300
Bagan, 2009, Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ). A concise update, Oral Oncology, 45, 551-4, 10.1016/j.oraloncology.2009.01.002
Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, Journal of Clinical Oncology, 23, 8580, 10.1200/JCO.2005.02.8670
Bennett, 2016, Hyperbaric oxygen therapy for late radiation tissue injury, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005005.pub4
Bermúdez-Bejarano, 2017, Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates, Journal of Clinical and Experimental Dentsitry, 9, e141
Bone, 2017, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, The lancet. Diabetes & endocrinology, 5, 513, 10.1016/S2213-8587(17)30138-9
Boquete-Castro, 2016, Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, Clinical Oral Implants Research, 27, 367, 10.1111/clr.12556
Chamizo Carmona, 2013, Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis, Reumatología clinica, 9, 172, 10.1016/j.reuma.2012.05.005
Chen, 2016, Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-Analysis of randomized controlled trials, Oncology Research and Treatment, 39, 453, 10.1159/000447372
Chestnut, 2001, Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites, Advances in Experimental Medicine and Biology, 496, 95, 10.1007/978-1-4615-0651-5_10
Coleman, 2011, Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer, Breast Cancer Research and Treatment, 127, 429, 10.1007/s10549-011-1429-y
Comas-Calonge, 2017, Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review, Journal of clinical and experimental dentistry, 9, e302, 10.4317/jced.53504
Copas, 2009, The radial plot in meta-analysis: approximations and applications, Journal of the Royal Statistical Society: Series C (Applied Statistics), 58, 329, 10.1111/j.1467-9876.2008.00650.x
Damm, 2013, Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays, General Dentistry, 61, 33
Dimopoulos, 2006, Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid, Haematologica, 91, 968
Diniz-Freitas, 2016, Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review, Medicina Oral, Patologia Oral y Cirugia Bucal, 21, e250, 10.4317/medoral.20963
Dodson, 2015, The frequency of medication-related ssteonecrosis of the jaw and its associated risk factors, Oral and Maxillofacial Surgery Clinics of North America, 27, 509, 10.1016/j.coms.2015.06.003
Eckardt, 2011, Surgical Management of Bisphosphonate-related Osteonecrosis of the Jaw in Oncologic Patients: A Challenging Problem, Anticancer Research, 31, 2313
Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, British Medical Journal, 315, 629, 10.1136/bmj.315.7109.629
El-Rabbany, 2017, Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis, The Journal of the American Dental Association, 148, 584, 10.1016/j.adaj.2017.04.002
Epstein, 2010, Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 110, 593, 10.1016/j.tripleo.2010.05.067
Fliefel, 2015, Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review, International Journal of Oral Maxillofacial Surgery, 44, 568-85, 10.1016/j.ijom.2015.01.026
Freiberger, 2009, Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws, Journal of Oral and Maxillofacial Surgery, 67, 96, 10.1016/j.joms.2008.12.003
Gerard, 2014, Early Inhibitory Effects of Zoledronic Acid in Tooth Extraction Sockets in Dogs Are Negated by Recombinant Human Bone Morphogenetic Protein, J Oral Maxillofac Surg, 72, 61, 10.1016/j.joms.2013.06.192
GRADE Working Group, McMaster University GRADEpro 2014
Grbic, 2010, The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program, The Journal of the American Dental Association, 141, 1365, 10.14219/jada.archive.2010.0082
Guarneri, 2010, Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer, Breast cancer research and treatment, 122, 181, 10.1007/s10549-010-0866-3
Guyatt, 2002, Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures, Endocrinology Metabolism Clinics of North America, 31, 659, 10.1016/S0889-8529(02)00024-5
Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, Journal of Clinical Oncology, 29, 1125, 10.1200/JCO.2010.31.3304
Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
Hinson, 2015, Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis, Journal of Oral and Maxillofacial Surgery, 73, 53, 10.1016/j.joms.2014.07.012
Kanis, 2007, Assessment of osteoporosis at the primary health-care level. Technical Report, 66
Katsarelis, 2015, Infection and medication-related osteonecrosis of the jaw, Journal of Dental Research, 94, 534, 10.1177/0022034515572021
Khan, 2015, Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus, Journal of Bone and Mineral Research, 30, 3-23, 10.1002/jbmr.2405
Kyrgidis, 2012, Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires, Anticancer Research, 32, 3527
Lee, 2007, Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases, J Oral Imlantol, 33, 371, 10.1563/1548-1336(2007)33[371:UOPPIT]2.0.CO;2
Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
Lopez-Jornet, 2010, Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study, Journal of Evaluation in Clinical Practice, 16, 878, 10.1111/j.1365-2753.2009.01203.x
Lopez-Jornet, 2016, Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review, Journal of Cranio-maxillo-facial Surgery, 44, 1067-72, 10.1016/j.jcms.2016.05.004
Lopez-Olivo, 2012, Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis, Supportive Care in Cancer, 20, 2985, 10.1007/s00520-012-1563-z
Martins, 2012, Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study, Oral Oncology, 48, 79, 10.1016/j.oraloncology.2011.08.010
Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, Journal of Oral and Maxillofacial Surgery, 61, 1115-7, 10.1016/S0278-2391(03)00720-1
Mauri, 2009, Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis, Breast Cancer Research and Treatment, 116, 433, 10.1007/s10549-009-0432-z
Migliorati, 2003, Bisphosphanates and oral cavity avascular bone necrosis, Journal of Clinical Oncology, 21, 4253, 10.1200/JCO.2003.99.132
Migliorati, 2010, How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care, The Journal of the American Dental Association, 141, 562, 10.14219/jada.archive.2010.0229
Miksad, 2011, Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw, The Oncologist, 16, 121, 10.1634/theoncologist.2010-0183
Morgan, 2010, First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, Lancet, 376, 1989, 10.1016/S0140-6736(10)62051-X
Nakamura, 2015, Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events, Journal of Pharmaceutical Health Care and Sciences, 22, 34, 10.1186/s40780-015-0035-2
Patel, 2015, New cancer therapies and jaw necrosis, British Dental Journal, 219, 203, 10.1038/sj.bdj.2015.680
Petrucci, 2007, Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients, Haematologica, 92, 1289, 10.3324/haematol.11096
Qi, 2014, Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials, International Journal of Clinical Oncology, 19, 403, 10.1007/s10147-013-0561-6
The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
Ripamonti, 2009, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Annals of Oncology, 20, 137, 10.1093/annonc/mdn526
Ripamonti, 2011, Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study, Oral Oncology, 47, 185, 10.1016/j.oraloncology.2011.01.002
Rollason, 2016, Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008455.pub2
Ruggiero, 2007, Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ), Clinical Cases in Mineral and Bone Metabolism, 4, 37, 10.1016/j.joms.2014.04.031
Ruggiero, 2014, American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update, Journal of Oral and Maxillofacial Surgery, 72, 1938, 10.1016/j.joms.2014.04.031
Rupel, 2014, A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ), Oral Oncology, 50(11), 1049-57
Saad, 2012, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases, Annals of Oncology, 23, 1341, 10.1093/annonc/mdr435
Scottish Dental Clinical Effectiveness Programme Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw Dundee, UK SDCEP
Sigua-Rodriguez, 2014, Bisphosphonate-related osteonecrosis of the jaw: a review of the literature, International Journal of Dentistry, 2014, 192320, 10.1155/2014/192320
Silva, 2016, Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review, Oral and Maxillofacial Surgery, 20(1), 1-17
Spanou, 2015, Management of bisphosphonate-related osteonecrosis of the jaw: a literature review, Oral Diseases, 21, 927-36, 10.1111/odi.12333
Stanton, 2009, Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases, Journal of Oral and Maxillofacial Surgery, 67, 943, 10.1016/j.joms.2008.12.057
Vescovi, 2006, Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment?, Journal of Oral and Maxillofacial Surgery, 64, 1460, 10.1016/j.joms.2006.05.042
Vescovi, 2012, Bisphosphonates and osteonecrosis: an open matter, Clinical Cases in Mineral and Bone Metabolism, 9, 142
Worthington, 2015, Priority oral health research identification for clinical decision-making, Evidence-Based Dentistry, 16, 69, 10.1038/sj.ebd.6401110
Xu, 2013, Denosumab and giant cell tumour of bone-a review and future management considerations, Current Oncology, 20, e442, 10.3747/co.20.1497